AbCellera Biologics (ABCL) Capital Expenditures (2020 - 2026)

AbCellera Biologics has reported Capital Expenditures for 7 years, with the latest figure at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 63.98% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $36.0 million (down 44.57% YoY), and the FY2025 full-year result was $42.8 million, down 45.44% from the prior year.
• Capital Expenditures for Q1 2026 stood at $3.8 million, down from $9.8 million in the prior quarter.
• The five-year high for Capital Expenditures was $31.3 million in Q2 2022, with the low at $3.8 million in Q1 2026.
• Historically, Capital Expenditures has averaged $16.0 million across 5 years, with a median of $14.5 million in 2022.
• Annual changes were most pronounced in 2022 — Capital Expenditures soared 297.78% — and 2026, when it plunged 63.98%.
• AbCellera Biologics' Capital Expenditures stood at $12.3 million in 2022, then rose by 17.04% to $14.4 million in 2023, then climbed by 8.31% to $15.6 million in 2024, then plunged by 37.02% to $9.8 million in 2025, then slumped by 61.08% to $3.8 million in 2026.
• The last three Capital Expenditures figures came in at $3.8 million (Q1 2026), $9.8 million (Q4 2025), and $8.9 million (Q3 2025), per Business Quant data.